Andere Sprachen Intellia Therapeutics, Inc.

Aktien

A2AG6H

US45826J1051

NTLA

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:27:01 01.05.2024			% 5 Tage	% 1. Jan.
22,66 ^USD	+5,86 %		+6,75 %	-25,88 %

15.04.	Intellia Therapeutics, Inc. ernennt Michael P. Dube zum Leiter der Buchhaltung	CI
25.03.	Intellia Therapeutics beendet Entwicklungsvereinbarung mit Regeneron Pharmaceuticals	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024	29.04.
Intellia Therapeutics : Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine - Form 8-K	15.04.
Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer	15.04.
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	25.03.
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	22.03.
Intellia Therapeutics Ends Co-Development Agreement With Regeneron	22.03.
Intellia Therapeutics : Termination of Material Agreement - Form 8-K	22.03.
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	18.03.
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	18.03.
North American Morning Briefing : Traders Await -2-	26.02.
Intellia Therapeutics Q4 Loss Widens	22.02.
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress	22.02.
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.02.
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis	15.02.
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	15.02.
Intellia Therapeutics, Inc. and ReCode Therapeutics Announces Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	15.02.
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates	15.02.
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates	14.02.
AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Intellia Therapeutics, Inc.

Aktien

A2AG6H

US45826J1051

NTLA

Andere Sprachen

Filter